标题
Antibody–drug conjugates in solid tumors: a look into novel targets
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-28
DOI
10.1186/s13045-021-01035-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies.
- (2020) Ian Churchill Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
- (2020) Jonathan Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- 138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
- (2020) G. Jerusalem et al. ANNALS OF ONCOLOGY
- Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
- (2020) Anas Gazzah et al. JOURNAL OF CLINICAL ONCOLOGY
- MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression.
- (2020) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
- (2020) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.
- (2020) Alessandro Santin et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
- (2020) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
- (2020) Valentina Boni et al. JOURNAL OF CLINICAL ONCOLOGY
- CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.
- (2020) Melissa Lynne Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
- (2020) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting the folate receptor α in oncology
- (2020) Mariana Scaranti et al. Nature Reviews Clinical Oncology
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort
- (2020) D.R. Camidge et al. ANNALS OF ONCOLOGY
- LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
- (2020) Y. Loriot et al. ANNALS OF ONCOLOGY
- LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
- (2020) R.L. Coleman et al. ANNALS OF ONCOLOGY
- LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
- (2020) H.A. Yu et al. ANNALS OF ONCOLOGY
- LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
- (2020) A. Bardia et al. ANNALS OF ONCOLOGY
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
- (2020) Elaine Chang et al. CLINICAL CANCER RESEARCH
- A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
- (2020) Clinton Yam et al. INVESTIGATIONAL NEW DRUGS
- SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
- (2019) Chang-yong Yang et al. ACTA PHARMACOLOGICA SINICA
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
- (2019) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- 151OSingle agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial
- (2019) K Yonemori et al. ANNALS OF ONCOLOGY
- Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.
- (2019) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.
- (2019) Hyo S. Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and role of HER2 mutations in cancer
- (2019) Emiliano Cocco et al. PHARMACOLOGY & THERAPEUTICS
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
- (2019) Heather Scharpenseel et al. Scientific Reports
- A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
- (2019) Yuuri Hashimoto et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer
- (2019) Shigehiro Koganemaru et al. MOLECULAR CANCER THERAPEUTICS
- ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
- (2019) Nicolas Kiavue et al. ONCOGENE
- Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates
- (2019) Wei Li et al. ACS Medicinal Chemistry Letters
- 992OFORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
- (2019) K Moore et al. ANNALS OF ONCOLOGY
- TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors
- (2019) Marco Gymnopoulos et al. Molecular Oncology
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.
- (2018) Alexandra Drakaki et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer
- (2018) Ying Zhang et al. Molecular Cancer
- 949PMirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
- (2018) U A Matulonis et al. ANNALS OF ONCOLOGY
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
- (2018) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
- (2018) John H. Strickler et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
- (2017) Efrat Dotan et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
- (2017) H.L. Kindler et al. Journal of Thoracic Oncology
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)
- (2016) A. Gazzah et al. EUROPEAN JOURNAL OF CANCER
- Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
- (2016) Carolin Sellmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
- (2015) Jessica R. McCombs et al. AAPS Journal
- Conformational Difference in Human IgG2 Disulfide Isoforms Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry
- (2015) Aming Zhang et al. BIOCHEMISTRY
- Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer
- (2015) Satoshi Nishiwada et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
- (2015) Boris Shor et al. MOLECULAR IMMUNOLOGY
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Signaling by epithelial members of the CEACAM family – mucosal docking sites for pathogenic bacteria
- (2014) Arnaud Tchoupa et al. Cell Communication and Signaling
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
- (2014) D. Sussman et al. MOLECULAR CANCER THERAPEUTICS
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis
- (2013) Nicole Beauchemin et al. CANCER AND METASTASIS REVIEWS
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma
- (2013) Anna Maria Athanassiadou et al. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Trop-2 signalling network in cancer growth
- (2012) E Guerra et al. ONCOGENE
- The relationship between tissue factor and cancer progression: insights from bench and bedside
- (2011) Y. W. van den Berg et al. BLOOD
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum
- (2010) Melissa S. DeRycke et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
- Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer
- (2009) A. Takano et al. CANCER RESEARCH
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- The ERBB3 receptor in cancer and cancer gene therapy
- (2008) G Sithanandam et al. CANCER GENE THERAPY
- Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation
- (2008) Yoshimi Takai et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Mesothelin targeted cancer immunotherapy
- (2007) Raffit Hassan et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search